Related Experiment Video

Updated: Jun 9, 2025

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome
07:23

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome

Published on: June 15, 2016

8.4K

Avelumab reduces STAT3 expression with effects on IL-17RA and CD15

Wojciech Kacper Szlasa1, Natalia Julia Sauer2, Jakub Karwacki3

  • 1Department of Minimally Invasive and Robotic Urology, University Center of Excellence in Urology, Wroclaw Medical University, Poland.

Dental and Medical Problems
|October 31, 2024
PubMed
Abstract

Insights

Avelumab treatment reduced STAT3 expression in renal cancer cells, altering CD15 and IL-17RA levels. This suggests PD-L1 targeting impacts novel anticancer therapy targets.

Area of Science:

  • Immunology
  • Oncology
  • Cell Biology

Background:

  • Avelumab targets programmed cell death ligand-1 (PD-L1) on cancer cells.
  • Cluster of differentiation 15 (CD15) and interleukin 17 receptor A (IL-17RA) are novel targets for renal cell carcinoma (RCC) therapy.
  • Signal transducer and activator of transcription 3 (STAT3) regulates PD-L1, CD15, and IL-17RA expression.

Purpose of the Study:

  • To investigate if avelumab targeting PD-L1 affects CD15 and IL-17RA expression.
  • To assess STAT3-mediated regulation of CD15 and IL-17RA in renal cancer.

Main Methods:

  • Immunocytochemistry (ICC) and confocal laser scanning (CLS) microscopy were used.
  • Expression and localization of targets were assessed in three RCC cell lines and one healthy renal cell line.
  • Cells were treated with 20 ng/mL avelumab.

Main Results:

  • Avelumab treatment reduced STAT3 expression in renal cancer cells.
  • CD15 expression increased in cancer cells with high IL-17RA, while membrane CD15 signal decreased.
  • CD15 expression decreased in other renal cancer cell lines; IL-17RA levels were unaffected in cancer cells but changed in healthy cells.

Conclusions:

  • Targeting PD-L1 with avelumab alters CD15 and IL-17RA expression.
  • CD15 and IL-17RA have prognostic and therapeutic roles in novel anticancer therapies.
  • STAT3 signaling is implicated in the regulation of these targets.
Keywords:
CD15IL-17RAavelumabmembrane antigen modulation

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.1K
Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes12:59

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Published on: September 26, 2013

34.4K

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
954
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
484